Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: Outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

BMC Neurology

Volumn 16, Issue 1, 2016, Pages

  Alcalde Cabero, Enrique ^a   Almazán Isla, Javier ^a   García López, Fernando J ^a   Ara Callizo, José Ramón ^b   Avellanal, Fuencisla ^a   Casasnovas, Carlos ^c   Cemillán, Carlos ^d   Cuadrado, José Ignacio ^e   Duarte, Jacinto ^f   Fernández Pérez, María Dolores ^g   FernandezOscar ^h   Merino, Juan Antonio García ⁱ   Montero, Rosa García ^j   Montero, Dolores ^k   Pardo, Julio ^l   Rodríguez Rivera, Francisco Javier ^m   Ruiz Tovar, María ^a   De Pedro Cuesta, Jesús ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e Ministry of Health   (Spain)

^f HOSPITAL GENERAL DE SEGOVIA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL VIRGEN DE LA SALUD   (Spain)

^k Agencia Espanola de Medicamentos y Productos Sanitarios   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

Guillain Barr syndrome; ICD 9 CM; Influenza A virus H1N1 subtype; Influenza vaccines; Public health surveillance; Safety

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE SURVEILLANCE; FEMALE; GENERAL HOSPITAL; GUILLAIN BARRE SYNDROME; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL DISCHARGE; HUMAN; ICD-9-CM; INCIDENCE; INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEURITIS; NEUROLOGIST; PILOT STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPAIN; EPIDEMIOLOGICAL MONITORING; FACTUAL DATABASE; GUILLAIN-BARRE SYNDROME; HEALTH SURVEY; IMMUNOLOGY; MIDDLE AGED; PANDEMIC; TIME FACTOR;

ADULT; AGED; DATABASES, FACTUAL; EPIDEMIOLOGICAL MONITORING; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEUROLOGISTS; PANDEMICS; PROSPECTIVE STUDIES; PUBLIC HEALTH SURVEILLANCE; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 84969548914     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-016-0598-z     Document Type: Article

References (35)

1. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-304.
2. Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Holmqvist LW. Disability and health-related quality of life in Guillain-Barré syndrome during the first two years after onset: a prospective study. Clin Rehabil. 2005;19(8):900-9.
3. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med. 1981;304(26):1557-61.
4. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol. 1991;133(9):940-51.
5. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339(25):1797-802.
6. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768-97.
7. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006;59(8):808-18.
8. McClure DL, Glanz JM, Xu S, Hambidge SJ, Mullooly JP, Baggs J. Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine. 2008;26(26):3341-5.
9. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461-8.
10. Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448-58.
11. Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015;33(31):3773-8.
12. Wu J, Xu F, Lu L, Lu M, Miao L, Gao T, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med. 2010;363(25):2416-23.
13. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ. 2011;343:d5956.
14. Ghaderi S, Gunnes N, Bakken I, Magnus P, Trogstad L, Håberg SE. Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study. Eur J Epidemiol. 2016;31(1):67-72.
15. Kim C, Rhie S, Suh M, Kang DR, Choi YJ, Bae GR, et al. Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea. Vaccine. 2015;33(15):1815-23.
16. Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia B, et al. Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health. 2012;102(10):1921-7.
17. Savulescu C, Jiménez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill. 2011;16(11):pii:19820.
18. Jiménez-Jorge S, de Mateo S, Pozo F, Casas I, García Cenoz M, Castilla J, et al. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. Euro Surveill. 2012;17(12):pii:20129.
19. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388.
20. Ministerio de Sanidad y Consumo. Real Decreto 2210/1995, de 28 diciembre, por el que se crea la red nacional de vigilancia epidemiológica. http://www.boe.es/diario_boe/txt.php?id=BOE-A-1996-1502. Boletín Oficial del Estado 24 enero 1996, núm. 21, 2153-2158. 28-12-1995. 1502. Accessed 3 Mar 2016.
21. Cuadrado JL, de Pedro-Cuesta J, Ara JR, Cemillán CA, Díaz M, Duarte J, et al. Guillain-Barré syndrome in Spain, 1985-1997: epidemiological and public health views. Eur Neurol. 2001;46(2):83-91.
22. Cuadrado JL, de Pedro-Cuesta J, Ara JR, Cemillán CA, Díaz M, Duarte J, et al. Public health surveillance and incidence of adulthood Guillain-Barré syndrome in Spain, 1998-1999: the view from a sentinel network of neurologists. Neurol Sci. 2004;25(2):57-65.
23. Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3(6):565-6.
24. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599-612.
25. Ministerio de Sanidad Servicios Sociales e Igualdad. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. www.msssi.gob.es. 2014. 25-2-2014. Accessed 3 Mar 2016.
26. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373-5.
27. Cheng Q, Jiang GX, Fredrikson S, Link H, de Pedro-Cuesta J. Epidemiological surveillance of Guillain-Barré syndrome in Sweden, 1996-1997. Network members of the Swedish GBS Epidemiology Study Group. Acta Neurol Scand. 2000;101(2):104-10.
28. Funch D, Holick C, Velentgas P, Clifford R, Wahl PM, McMahill-Walraven C, et al. Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases. Vaccine. 2013;31(16):2075-9.
29. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169(3):382-8.
30. Kwong JC, Vasa PP, Campitelli MA, Hawken S, Wilson K, Rosella LC, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis. 2013;13(9):769-76.
31. Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barré syndrome, influenza-related hospitalizations, and influenza vaccine coverage. Vaccine. 2015;33(17):2045-9.
32. de Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308(2):175-81.
33. Galeotti F, Massari M, D'Alessandro R, Beghi E, Chio A, Logroscino G, et al. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol. 2013;28(5):433-44.
34. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343:d3908.
35. Giambrone GP, Zansky SM, Eidson M, Duncan PG, McNutt LA, Birkhead GS. Guillain-Barré syndrome surveillance during National Influenza Vaccination Campaign, New York, U.S.A., 2009. Emerg Infect Dis. 2013;19(12):1956-62.